Skip to main content
Fig. 1 | Health and Quality of Life Outcomes

Fig. 1

From: Longitudinal assessment of utilities in patients with migraine: an analysis of erenumab randomized controlled trials

Fig. 1

Estimated EQ-5D mean utility values by MMD frequency for erenumab and placebo, mapped from MSQ. Abbreviations: CI confidence interval, EQ-5D 5-dimension EuroQol questionnaire, FRM fractional response model, MMD monthly migraine day, MSQ Migraine-Specific Quality of Life Questionnaire, REML restricted maximum likelihood. Observed values with 95% CIs are represented by blue, green and red vertical lines for erenumab 140 mg and 70 mg and placebo, respectively. (a) Linear mixed effects model with REML, (b) FRM (logit), (c) FRM (probit), (d) Beta regression model

Back to article page

Health and Quality of Life Outcomes

ISSN: 1477-7525

Contact us